
Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker

Merlintrader Trading Pub
Biotech catalyst, news and analysis PDUFA tracker
AI transparency: articles and reports are produced with the help of artificial intelligence and checked through a process that does not constitute specialist validation. They may contain errors: verify relevant information with independent sources. Read the full disclaimer.
Nov 17, 2026, 9:41 PM ET
Maxim raises SELLAS price target to $40 from $30 after Phase 3 REGAL results
Nasdaq: $SLSClinical-stage oncologyREGAL Phase 3 met primary endpointRegulatory and dilution risk
SLS Stock Hub: SELLAS Life Sciences News, REGAL Phase 3 Results and SLS009
On November 17, 2026 SELLAS reported that the pivotal Phase 3 REGAL trial of galinpepimut-S (GPS) in acute myeloid leukemia (AML) met its primary endpoint of overall survival: median overall survival of 24.0 months versus 14.7 months with best available treatment, a hazard ratio of 0.59 and a two-sided p=0.035. The company plans to meet the FDA and to submit a Biologics License Application in the first half of 2027. First-line SLS009 enrollment reached 40 of 80 patients at the November 12 update, with preliminary topline data still expected in Q4 2026. The company held $134.7 million in cash at September 30, after substantial warrant-driven dilution. Completed Phase 2 data for SLS009 in relapsed or refractory AML are scheduled as a poster at the American Society of Hematology (ASH) meeting on December 14. SELLAS also announced a proposed $150 million public offering, adding a new dilution event distinct from the at-the-market (ATM) program.
Full research report · PDF
SELLAS Life Sciences research updated November 17, 2026
20 pages · Positive Phase 3 REGAL overall-survival results, planned FDA meeting and GPS BLA, first-line SLS009 and ASH data, financial resources and dilution risks.
Next catalyst · scheduled presentation and company guidance
December 14, 2026 · SLS009 ASH poster; first-line SLS009 topline in Q4 2026
REGAL has read out: on November 17, 2026 SELLAS announced that the Phase 3 trial met its overall-survival primary endpoint (hazard ratio 0.59, two-sided p=0.035; median 24.0 versus 14.7 months). On the GPS side the company now plans to meet the FDA to discuss an accelerated filing strategy and to submit a BLA in the first half of 2027; no FDA meeting date has been disclosed. Source: company release, November 17 · Form 8-K
SLS009: ASH 2026 poster (abstract 5155) on December 14, 6:00–8:00 p.m. CST, with the completed relapsed/refractory Phase 2 (November 4 release); preliminary first-line topline guided for Q4 2026, with 40 of 80 patients enrolled at the November 12 update. Detailed REGAL results, including the secondary endpoints, are to be presented at an upcoming major medical conference, not yet named.
SLS stock at a glance
Chart analysis · JC
Technical chart analysis of $SLS with bull and bear scenarios on JC Just Charts.
Cash · Sep 30, 2026
$134.7M
Cash and equivalents; $138.3M at June 30 and $71.8M at December 31, 2025.
Operating cash use · 9M 2026
$22.4M
Net cash used in operations in the nine months to September 30; distinct from the $28.1M nine-month net loss.
Shares · Nov 11, 2026
203.86M
Basic shares outstanding (Form 10-Q cover); 153.10M at December 31, 2025.
Warrants · Sep 30, 2026
8.12M
Remaining warrants, alongside the $150M ATM still unused at the November 12 filing.
Short shares · Oct 30 settlement
57.13M
Nasdaq: up 6.26% from October 15; 6.70 days to cover versus 11.95 previously.
SLS009 enrollment · Nov 12
40 / 80
First-line AML Phase 2; preliminary topline expected in Q4 2026, with sample size at readout undisclosed.
Where SELLAS stands now
SELLAS is a pre-commercial oncology company with two AML programs: the immunotherapeutic galinpepimut-S (GPS), which targets the Wilms Tumor 1 protein (WT1), in Phase 3 REGAL, and the selective CDK9 inhibitor SLS009 (tambiciclib). The balance sheet gives it room to work through the next steps toward a potential GPS filing. Source: Q2 Form 10-Q.
On November 17, 2026 SELLAS announced that REGAL met its primary endpoint. The trial randomized 126 patients 1:1 to GPS maintenance monotherapy or investigator’s choice of best available treatment, in AML patients in second or later complete remission who were ineligible for, or unable to undergo, allogeneic stem cell transplantation. The analysis, run after the prespecified 80 deaths, showed a 41% reduction in the risk of death (hazard ratio 0.59, two-sided p=0.035), with median overall survival of 24.0 months on GPS versus 14.7 months with best available treatment. The company describes GPS as generally well tolerated, with treatment-related adverse events predominantly grade 1/2, mostly local injection-site reactions, and no new safety signals. Evaluation of the secondary endpoints is underway; SELLAS plans to meet the FDA and to submit a BLA in the first half of 2027. Company release · Form 8-K
On November 12, 2026 SELLAS reported third-quarter results: $134.7 million of cash and equivalents at September 30, a quarterly net loss of $10.1 million, or $0.05 per share, versus $6.8 million a year earlier, with R&D expenses of $7.0 million and G&A of $4.3 million. Operating activities used $22.4 million in the first nine months of 2026, while warrant exercises brought about $85.1 million. At that date the company guided REGAL topline primary-endpoint results to November, after database lock, blinded data review, statistical analysis and unblinding, and reported them on November 17; first-line SLS009 enrollment reached 40 of 80 patients, with preliminary topline data expected in Q4 2026. The Form 10-Q states that cash is expected to fund planned operations for at least twelve months and that no shares had been sold under the $150 million ATM; the cover reports 203,859,151 shares at November 11. Third-quarter release · Q3 Form 10-Q
Financing update · November 17, 2026. SELLAS commenced a proposed $150 million underwritten public offering of newly issued common stock, with an intended 30-day underwriter option for up to a further $22.5 million. J.P. Morgan and TD Cowen are joint book-running managers. Pricing, the number of shares and completion were not announced in this proposed-offering release. The transaction is subject to market and other conditions. It is separate from the existing $150 million ATM; proposed gross proceeds are not cash already received. Company offering announcement, November 17, 2026.
The main risk now: a positive topline is not an approval. REGAL met its primary endpoint in a 126-patient, open-label trial with a two-sided p=0.035. The FDA has not yet reviewed the data, the secondary-endpoint analyses are still underway, and the company itself cites the risk that final results or further analyses differ from topline or do not support submission or approval. The November 17 proposed $150 million public offering creates a specific new dilution event, separate from the unused ATM, with pricing and completion still unannounced.
The constructive case
REGAL met its overall-survival primary endpoint on November 17, 2026 (median 24.0 versus 14.7 months, hazard ratio 0.59), with a safety profile the company describes as consistent with prior experience and no new safety signals, and SELLAS plans a BLA submission in the first half of 2027. The September 30 cash balance was $134.7M, and the company reported no ATM sales through the November 12 filing. SLS009 adds a second AML program, backed by a response signal in relapsed/refractory disease and an ongoing first-line study. Those assets give SELLAS more than one development path.
The cautious case
The REGAL result is a topline summary: the FDA may not agree with the company’s analyses or filing strategy, the trial was open-label with 126 patients, and the detailed secondary endpoints are not yet public. SLS009’s earlier response data come from a small, nonrandomized study, and the pancreatic-cancer work remains preclinical. Cash grew through warrant exercises, alongside dilution; future manufacturing, regulatory and clinical spending can exceed the nine-month pace, and R&D already rose to $7.0M in the third quarter as the company prepares a potential GPS BLA. The proposed $150 million public offering announced November 17 adds issuance risk on top of the unused ATM.
Latest SELLAS Life Sciences news
Nov 17, 2026
Maxim raises SELLAS price target to $40 from $30 after Phase 3 REGAL results
Maxim Group raised its SELLAS price target to $40 from $30 and left its rating unchanged after the Phase 3 REGAL results. In the 126-patient trial, median overall survival was 24 months with galinpepimut-S (GPS) versus 14.7 months with investigator-selected best available therapy. The company reported a hazard ratio of 0.59, a p-value of 0.035 and a 41% reduction in the risk of death. Alliance Global Partners said GPS could win expedited FDA approval in 2027. Analyst action reported by the press; it is the bank's view, not Merlintrader's.
Nov 17, 2026
SELLAS Life Sciences announces proposed $150.0 million underwritten public offering
SELLAS Life Sciences Group, Inc. announced it has commenced an underwritten public offering of $150.0 million of its common stock, with all shares sold by the company. The underwriters have a 30-day option to purchase up to an additional $22.5 million of shares. J.P. Morgan and TD Cowen are acting as joint book-running managers, and the offering is being made under a shelf registration statement on Form S-3.
Nov 17, 2026
SELLAS Life Sciences announces positive Phase 3 REGAL trial data for GPS vaccine
SELLAS announced positive topline results from the pivotal Phase 3 REGAL trial of galinpepimut-S (GPS) in acute myeloid leukemia. The trial met its primary overall survival endpoint, with a 41% reduction in risk of death, a hazard ratio of 0.59 (p=0.035), and median overall survival of 24.0 months versus 14.7 months for best available treatment. The company plans to meet with the FDA to discuss an accelerated filing strategy and is advancing preparations for a BLA submission in the first half of 2027. A webcast to discuss the results was held on November 17, 2026.
Nov 13, 2026
SELLAS expects leukemia trial results later this month, CEO calls treatment potentially transformative
SELLAS Life Sciences expects to report results from its key leukemia trial later this month. Its CEO said the treatment could become a "transformative" immunotherapy if the trial is successful. Unconfirmed report based on unnamed sources; not confirmed by the company.
Nov 12, 2026
SELLAS Life Sciences reports third quarter 2026 financial results and provides corporate update
SELLAS reported a net loss of $10.1 million for the third quarter of 2026, or $0.05 per share, compared with a net loss of $6.8 million in the same quarter of 2025. Research and development expenses were $7.0 million and general and administrative expenses were $4.3 million for the quarter. Cash and cash equivalents totaled $134.7 million as of September 30, 2026. The company expects topline primary endpoint results from the Phase 3 REGAL trial of GPS this month, and preliminary topline data from the Phase 2 trial of SLS009 in newly diagnosed AML in Q4 2026.
Nov 10, 2026
State Street discloses 5.1% Sellas stake as Victory Capital raises holdings sharply
State Street reported a 5.1% stake in Sellas, or 10.37 million shares as of Sept. 30, down about 20% from nearly 13 million shares on June 30. Victory Capital raised its holding 982% to 231,562 shares. Voya, FMR, UBS and Nuveen also added shares, while Zurcher Kantonalbank and William Blair cut theirs. Sellas expects preliminary Regal topline results in the fourth quarter after the trial reached its 80th event. Not confirmed by a company release or filing at the time of writing; to be verified.
SLS stock catalysts: the dated calendar
- October 28, 2026 — REGAL final-analysis trigger announced. Completed announcement
- November 12, 2026 — Third-quarter results: $134.7M cash at September 30; REGAL topline then guided to November; SLS009 first-line enrollment 40 of 80. Completed
- November 17, 2026 — REGAL topline: primary endpoint met, median overall survival 24.0 versus 14.7 months, hazard ratio 0.59, two-sided p=0.035. Completed
- Q4 2026 — First-line SLS009 Phase 2 preliminary topline; no exact date or readout sample size specified. Company guidance, reiterated November 12
- December 14, 2026 · 6:00–8:00 p.m. CST — ASH 2026 poster (abstract 5155): completed Phase 2 of SLS009 with azacitidine and venetoclax in relapsed or refractory AML after prior venetoclax. Scheduled scientific presentation
- December 30, 2026 — Primary completion listed for the broader SLS009 Phase 1/2a record, updated September 3. This differs from the company’s topline window. Registry estimate
- Date not announced — Meeting with the FDA on an accelerated filing strategy for GPS; detailed REGAL results, including secondary endpoints, at an upcoming major medical conference. Company plan, November 17
- First half of 2027 — Planned BLA submission for GPS. Company plan, November 17
- Announced November 17, 2026 · pricing and completion not fixed — Proposed $150M public offering, plus intended $22.5M option; separate from the ATM. Proposed financing, subject to conditions. Company offering announcement, November 17, 2026.
REGAL topline release, November 17 · November 12 quarterly release · REGAL announcement · SLS009 guidance · SLS009 registry · ASH 2026 SLS009 data
REGAL, GPS and the SLS009 pipeline
PIVOTAL PHASE 3
GPS · REGAL in AML
GPS targets WT1. REGAL tests maintenance treatment after second complete remission, with overall survival as the primary endpoint. The final analysis, run after the prespecified 80 deaths, met the primary endpoint: on November 17, 2026 SELLAS reported median overall survival of 24.0 months with GPS versus 14.7 months with best available treatment among 126 randomized patients (hazard ratio 0.59, two-sided p=0.035). GPS remains investigational and the FDA has not reviewed the data.
PHASE 2
SLS009 · CDK9 inhibition
At ASH 2025, the combination with azacitidine and venetoclax produced a 46% response rate among 35 evaluable relapsed/refractory patients with AML with myelodysplasia-related changes (AML-MR), including 29% complete remission or complete remission with incomplete hematologic recovery (CR/CRi). The first-line study is a separate clinical test, with 40 of 80 enrolled as of the November 12 update. On November 4, 2026 SELLAS reported results from the completed Phase 2 in 62 heavily pretreated patients after venetoclax-based therapy, to be presented at ASH: overall response rate 34% across all doses (n=59; 12 CR/CRi and 8 morphologic leukemia-free state (MLFS)); at the selected 30 mg twice-weekly dose, 54% with 5.8 months median overall survival in monocytic AML and 57% with 8.8 months in TP53-mutated AML, which the company compares with historical outcomes of about 2.5 months. The comparison is with historical data, not a randomized control arm. Company release.
PRECLINICAL
Pancreatic-cancer research
The September organoid findings support further work on CDK9 and MYC-driven resistance. They do not demonstrate efficacy in pancreatic-cancer patients or establish a clinical development timetable.
SLS cash, burn and share dilution
| Item | Dated position |
|---|---|
| Cash and operating burn | $134.7M cash at September 30 ($138.3M at June 30); $22.374M used in operations in the first nine months of 2026, of which $16.434M in H1. Management says cash funds planned operations for at least twelve months from the November financial statements. |
| Warrant exercises | About $85.1M of warrant-exercise proceeds in the first nine months of 2026. Basic shares rose from 153.10M at year-end 2025 to 203.86M at November 11. |
| Remaining warrants | 8.12M at September 30 (9.71M at June 30). Other equity awards and reserved plan shares are separate. |
| ATM capacity | Up to $150M under the March 2026 agreement with TD Cowen. No sales reported through the November 12 filing date. |
| Licence obligations | SLS009 milestones of up to $48M for development/regulatory progress and $92M for sales, plus tiered royalties; contingent ceilings rather than current payables. |
| Proposed public offering · November 17 | $150M proposed primary common-stock offering, plus intended $22.5M underwriter option. No pricing or completion announced in the release; separate from the ATM. Company offering announcement, November 17, 2026. |
SELLAS Life Sciences deep dive: the full analysis
The business, clinical evidence, funding and ownership behind the current SLS stock picture, updated through November 17, 2026. The Merlintrader Research Library collects our dated biotech stock research reports.
01 SLS stock scenarios after the REGAL result
Merlintrader reading, November 17, 2026. The scenarios start from a disclosed positive trial result. SELLAS reported that REGAL met its overall-survival primary endpoint: median survival was 24.0 months with GPS versus 14.7 months with best available treatment, hazard ratio 0.59 and two-sided p=0.035, in 126 randomized patients. These are company-reported topline results. They have not yet become an FDA assessment, an approved label or commercial revenue.
Bull scenario: clinical evidence becomes a credible filing
The constructive case is that the detailed dataset supports the topline, the FDA agrees on a workable filing strategy, and manufacturing and quality work progress alongside the planned first-half 2027 BLA submission. SLS009 would add an independent development opportunity if the first-line AML results support further study. The funding already on the balance sheet gives management choices about how to sequence those tasks. It does not remove the cost of them.
Base scenario: progress with unresolved regulatory work
The central operating scenario is a period of data presentation, FDA interaction and submission preparation, with SLS009 still in development. GPS remains investigational. Detailed survival curves, subgroup analyses, follow-up and secondary endpoints can qualify the initial interpretation. Cash spending may increase as the company prepares a possible filing and continues trials, so a successful efficacy headline can coexist with further financing.
Bear scenario: the path after topline is harder than expected
The cautious case is that the full analysis reveals limitations, the regulator asks for additional evidence, or manufacturing and submission work take longer and cost more. SLS009 could disappoint or provide a dataset too immature to settle the first-line question. Dilution would then matter even with the September cash balance, because financing needs depend on the future development plan. A positive primary endpoint reduces one specific uncertainty; it does not eliminate the remaining scientific, regulatory and operating risks.
These are conditional operating scenarios, without probabilities or security-price targets. Their tests are observable: detailed REGAL data, a documented regulatory path, SLS009 outcomes, cash use and actual issuance. An acquisition or licensing agreement would be an additional event requiring its own primary disclosure, not an assumption embedded in the base case.
What would falsify this reading
Merlintrader reading, November 17, 2026. This analysis rests on four propositions: the reported REGAL result supplies meaningful clinical evidence; the balance sheet supports the next development steps; SLS009 provides a separate but unproven AML opportunity; and outstanding equity instruments remain material to the ownership claim. The following observations would change that interpretation.
- Clinical detail inconsistent with the topline interpretation. A material revision of the survival analysis, important safety findings, limited durability or subgroup dependence would require reassessing the strength of the GPS case. A hazard ratio alone cannot settle every question about applicability to a future label.
- A materially different FDA path. A requirement for additional clinical work or a substantial manufacturing issue would alter the timetable and capital needs. The company’s first-half 2027 submission plan is a forward-looking plan, rather than an agency commitment.
- SLS009 results that fail to support the earlier signal. A delay, a small or immature first-line dataset, weak durability or unacceptable toxicity would reduce its contribution as a second development pillar. Historical-control comparisons cannot substitute for the trial’s own evidence.
- A change in the funding trajectory. Operating spending well above the reported pace, a new financing, an ATM sale or a major commitment would change the per-share funding picture. The September 30 cash figure does not describe the current bank balance.
- A change to licensed rights. A disclosed amendment, termination or new obligation could alter the economic rights to GPS or SLS009. The Greater China milestone ceiling is contingent and outside SELLAS’s control; it is not a receivable assumed in the runway.
None of these conditions is a prediction. They identify what evidence could overturn the current reading and prevent a favorable result from becoming an unfalsifiable investment story.
02 What SELLAS Life Sciences does: two different AML approaches
SELLAS is headquartered in New York and describes itself as a late-stage clinical biopharmaceutical company focused on novel therapies for a broad range of cancers. Its two lead clinical programs focus on acute myeloid leukemia. GPS was tested in the pivotal Phase 3 REGAL survival study in AML patients who reached complete remission after second-line salvage therapy. SLS009 has been studied in relapsed/refractory AML and is being studied in newly diagnosed high-risk AML patients unlikely to benefit from standard azacitidine plus venetoclax.
GPS, licensed from Memorial Sloan Kettering Cancer Center, targets the Wilms Tumor 1 protein (WT1), which is overexpressed in several hematologic malignancies and solid tumors. It has been studied in AML, mesothelioma, multiple myeloma and other settings, and SELLAS reported a positive randomized overall-survival result on November 17, 2026. Whether those results support an approvable filing remains a regulatory question.
SLS009, licensed from GenFleet Therapeutics in 2022 for territories outside Greater China, changed the shape of the company. It addresses a different problem with a different mechanism: transcriptional survival signals in high-risk AML biology, including resistance to venetoclax. The two assets do not repeat one scientific bet; they cover different stages of the disease. SELLAS has no marketed product, so its value rests on readouts, regulatory probability, financing flexibility and execution, which is why event-count updates, conference abstracts and warrant exercises move the shares.
Regulatory designations. According to the Q2 2026 Form 10-Q, GPS holds FDA Orphan Drug designations and EMA orphan medicine designations in AML, malignant pleural mesothelioma and multiple myeloma, FDA Fast Track designations in the same three indications and, since October 2024, FDA Rare Pediatric Disease designation for pediatric AML. SLS009 holds FDA Orphan Drug designations in AML and peripheral T-cell lymphoma (PTCL), FDA Fast Track designations in relapsed/refractory AML and relapsed/refractory PTCL, FDA Rare Pediatric Disease designations for pediatric acute lymphoblastic leukemia (June 2024) and pediatric AML (July 2024), and EMA orphan designations in AML (June 2024) and PTCL (July 2024). Designations of this kind bring procedural and commercial advantages, such as closer FDA interaction under Fast Track and orphan market exclusivity if a product is approved, but none of them says anything about whether a drug works.
Company overview and program descriptions, Q3 2026 Form 10-Q.
GPS result, November 17, 2026.
Q2 Form 10-Q: historical regulatory designations and company description.
03 SLS stock catalysts: what remains ahead
The October 28, 2026 announcement that REGAL reached its 80th death was the trigger for the final analysis. The November 17 topline announcement supplied the comparative result. Those are completed milestones. The next GPS checkpoints are presentation of detailed results, FDA interaction and the company’s planned BLA submission in the first half of 2027. SELLAS has not supplied a fixed date for the FDA meeting or detailed-results presentation in the November 17 release.
SLS009 has a separate calendar. The November 12 quarterly update reported 40 of 80 patients enrolled in the first-line AML Phase 2 study and reiterated preliminary topline in Q4 2026. The company did not identify the eventual readout sample size. An enrollment target is not the number of patients with evaluable follow-up at a particular disclosure. The completed relapsed/refractory study being presented at ASH is another dataset, with a different treatment setting and prior-therapy profile.
The ASH 2026 poster is scheduled for December 14, from 6:00 to 8:00 p.m. CST, abstract 5155. The November 4 release already describes results from the completed Phase 2 study. The conference can add scientific detail and discussion; its date is not a promise that first-line topline will be published at the same time. The broader NCT04588922 registry lists estimated primary completion on December 30, 2026 in its September 3 update. A registry estimate and corporate topline guidance describe different milestones.
Merlintrader reading: the most useful calendar distinguishes completed results, scheduled scientific events, company plans and registry estimates. A change to any of these requires a dated disclosure. Meanwhile, actual spending, enrollment, manufacturing readiness and regulatory communication provide more information than assigning an exact date to an unspecified future announcement.
04 The SELLAS story: from event counts to a disclosed result
The SELLAS story began with GPS and the idea that WT1, overexpressed in many cancers but scarcely present in most normal adult tissue, could be an immunotherapy target. Over time the market narrowed its attention to the program closest to a decisive catalyst: GPS in AML. REGAL was designed to test it in patients in second complete remission who are not proceeding to transplant, a group in which remission after salvage therapy does not equal cure and relapse risk stays high.
SELLAS announced the completion of REGAL enrollment in March 2024, as its Q2 2026 Form 10-Q recounts; its August 7, 2025 release dates completion to April 2024 with 126 patients randomized, while the ClinicalTrials.gov record lists 127. The study is open-label and event-driven, with the final analysis after 80 deaths. The protocol also called for an interim safety, efficacy and futility analysis after 60 events: that threshold was reached in December 2024, and on January 23, 2025 SELLAS announced a positive outcome, with the Independent Data Monitoring Committee (IDMC) recommending that the trial continue without modification. On August 7, 2025 SELLAS reported a further, periodic IDMC review with the same recommendation, and its annual report states that the committee has met several times and recommended continuation in each instance. Merlintrader reading: the committee recommended continuation without modification; its recommendation was not itself a declaration of efficacy. In the same August 7, 2025 release SELLAS said it expected the 80th event by the end of 2025. On December 29, 2025 it reported 72 events as of December 26, below that expectation. Traders read the slower pace as a possible sign of longer survival on GPS; the narrower reading is that it is compatible with that hypothesis without proving it. On May 12, 2026 SELLAS reported 78 events as of May 11, leaving two to the trigger. On October 28, 2026 it announced that the 80th event had been reached.
In parallel, SLS009 turned the company into a two-asset AML story. CDK9 regulates transcription of short-lived survival proteins such as MCL-1, a known route of resistance to venetoclax. At ASH 2025 SELLAS reported that SLS009 plus azacitidine and venetoclax achieved a 46% overall response rate in 35 evaluable relapsed/refractory AML-MR patients previously treated with venetoclax-based regimens, including 29% CR/CRi, with median overall survival of 8.9 months in the least pretreated cohort. Those results supported expansion into newly diagnosed high-risk AML, where the first patient was enrolled in March 2026, and in 2026 the company added preclinical work, including a poster at the AACR Annual Meeting on April 21, 2026, announced on March 17, and the pancreatic-cancer organoid data of September.
On November 17, 2026 SELLAS reported that the final REGAL analysis met its primary endpoint, with hazard ratio 0.59 and two-sided p=0.035. This changes the question from whether the primary endpoint will succeed to how the full evidence translates into a regulatory submission and an eventual treatment decision. The earlier event-count history explains the sequence; it no longer supplies the main efficacy evidence.
Final REGAL topline, November 17, 2026.
Q2 2026 Form 10-Q: REGAL enrollment and interim-review history · May 12, 2026 company update: 78 events as of May 11 · October 28, 2026 final-analysis trigger.
January 23, 2025 company release: interim analysis · Q2 2025 corporate update: August 7 IDMC review · December 29, 2025 company release: 72 events at December 26.
05 REGAL and GPS: what the positive topline establishes
REGAL is an open-label, randomized Phase 3 study comparing galinpepimut-S with investigator-selected best available treatment as maintenance in AML after a second complete remission. GPS is a WT1-targeting immunotherapeutic licensed from Memorial Sloan Kettering Cancer Center. The purpose is to train an immune response against cells expressing the target after remission.
The November 17, 2026 company release reports median overall survival of 24.0 months in the GPS arm versus 14.7 months in the control arm, a hazard ratio of 0.59 and two-sided p=0.035 among 126 randomized patients. The analysis followed the prespecified 80 events. The company describes a 41% reduction in the risk of death. That is a relative hazard description from the analysis, not a statement that 41% of patients are cured or that every treated patient lives a fixed additional number of months.
Merlintrader calculation: subtracting the two reported medians gives a 9.3-month difference. This arithmetic summarizes the reported arm medians. It is not an individual patient’s predicted benefit and does not describe every point on the survival curves. Medians and hazard ratios answer different questions, and the detailed curves and follow-up remain important for interpretation.
SELLAS said treatment-related adverse events were predominantly grade 1 or 2, mainly local injection-site reactions, with no new safety signal. That statement is attributed to the company’s topline disclosure. Complete adverse-event tables, exposure, discontinuations and follow-up are more informative than a brief safety summary for deciding how the treatment could fit a vulnerable maintenance population.
The disclosed next steps are discussion with the FDA on an accelerated filing strategy and preparation for a BLA submission in the first half of 2027. An accelerated filing strategy in the company’s language does not demonstrate accelerated approval, an accepted application, priority review or an approval date. The agency will evaluate the evidence and manufacturing package through its own process. GPS remains investigational as of November 17.
The event-count debate is now historical. Before topline, reaching 80 deaths did not reveal which randomized arm was doing better. Slow accrual could have reflected survival in either arm, patient selection or chance. After topline, the reported comparative analysis is the relevant efficacy disclosure. Institutional ownership, manufacturing expenditure and executive contracts were never substitutes for those results and do not become regulatory evidence after them.
Merlintrader reading: the primary endpoint is a substantial development milestone, while confirmation through detailed data, regulatory review and execution remains ahead. The evidence should be judged on the enrolled population and treatment comparison actually studied. A result in post-remission AML does not automatically establish benefit in other cancers or in earlier treatment settings.
SELLAS primary topline and safety disclosure, November 17, 2026.
06 SLS009 and CDK9 inhibition: mechanism, cohorts and limits
SLS009 is what makes SELLAS more than a one-trial setup. CDK9 drives transcription of short-lived proteins that cancer cells depend on, and one of the most discussed in AML is MCL-1, often linked to resistance to venetoclax. Venetoclax plus azacitidine is the standard backbone for patients unfit for intensive chemotherapy, but many relapse or become refractory, and outcomes after venetoclax failure are poor. If resistance involves a shift from BCL-2 dependence toward MCL-1, a selective CDK9 inhibitor that suppresses those survival signals has a clear rationale. SELLAS has reported reductions in MCL-1 and survivin in AML cell lines and activity in adverse-risk subtypes.
The ASH 2025 data drove the reappraisal. In relapsed/refractory AML-MR patients previously treated with venetoclax-based regimens, SLS009 plus azacitidine and venetoclax produced a 46% overall response rate among 35 evaluable patients, including 29% complete remission or complete remission with incomplete hematologic recovery (CR/CRi), with response rates of 48% in ASXL1-mutated and 57% in TP53-mutated patients and no dose-limiting toxicities or treatment-related deaths in the reported dataset. Median overall survival reached 8.9 months in the least pretreated cohort and had not been reached in patients with one prior line. The study was small and not randomized, response does not always translate into survival, and cross-trial comparisons are fragile; the signal was nonetheless strong enough to justify earlier-line development.
At an End-of-Phase-2 meeting announced on July 15, 2025, according to SELLAS, the FDA recommended proceeding into a trial including newly diagnosed first-line AML patients eligible for azacitidine and venetoclax. That company-reported advice helped shape the first-line program. It was not an approval or a conclusion that the proposed regimen had already demonstrated benefit in newly diagnosed patients. Q3 Form 10-Q, clinical-development discussion.
The cautious reading is that SLS009 remains in development: selectivity and tolerability claims need to hold up across larger, longer-followed datasets. The company-guided first-line topline window is Q4 2026, without a fixed date.
The current first-line position and the separate ASH dataset
The November 12, 2026 update reported that, as of November 5, the randomized first-line Phase 2 study had enrolled 40 of 80 planned patients, with preliminary topline guided to Q4 2026. The release does not specify how many patients will be in the preliminary analysis or the maturity of their follow-up.
The November 4 ASH release describes the completed relapsed/refractory Phase 2 study in 62 heavily pretreated patients after venetoclax-based treatment. The company reports a 34% overall response rate across doses among 59 evaluable patients: 12 CR/CRi and 8 MLFS. At the selected 30 mg twice-weekly dose, reported response and median-survival figures were 54% and 5.8 months in monocytic AML, and 57% and 8.8 months in TP53-mutated AML. The company’s comparison with approximately 2.5 months of historical survival is not a randomized control comparison.
Merlintrader reading: older ASH 2025 figures, the completed study described in November 2026 and the first-line study are related stages of development, with different denominators and treatment histories. They must not be pooled into a single response rate. The first-line result will need its own account of patient selection, comparator, response definitions, durability and safety before it can change the evidence standard.
November 12 first-line enrollment update.
07 Pancreatic-cancer research: why the organoid evidence is early
The September 25, 2026 company release describes work by researchers at the University of Wisconsin–Madison using patient-derived pancreatic ductal adenocarcinoma organoids. The models included MYC-amplified disease and a model resistant to the RAS inhibitor daraxonrasib. This is a mechanistic extension of the CDK9 program into a solid-tumor setting, rather than a clinical demonstration that SLS009 treats pancreatic cancer.
In the resistant model, the company reported 17.9% apoptosis with SLS009 versus 2.8% with daraxonrasib, and 14.5% necrosis versus 2.7%. The combination produced 36.5% apoptosis and 30.6% necrosis. The experiment used a 24-hour SLS009 exposure with assessment at 72 hours. These numbers describe the experimental conditions and endpoints in that laboratory model. They are not patient response rates or survival estimates.
SELLAS also described activity with the BET inhibitor ZEN3694 and suppression of MYC. SELLAS presented three posters on this work at the September 2026 pancreatic-cancer conference. A plausible biological mechanism is useful for selecting further experiments, but activity in a model does not demonstrate human exposure, tolerability, tumor penetration, dose schedule or clinical efficacy. Combination activity also does not show which patient population, if any, will benefit in a future study.
Merlintrader reading: the next evidence threshold is a documented clinical-development step, such as a trial registration, a protocol or a company announcement identifying the program and study design. Until then, pancreatic work adds research optionality and potential future expenditure. It should not be combined with the AML clinical response rates or used to infer a new commercial indication. The current GPS result likewise does not validate SLS009 in a different mechanism and tumor setting.
08 SELLAS Q3 earnings, cash and operating burn
The latest quarterly statements are for September 30, 2026, filed on November 12. SELLAS reported approximately $134.7 million in cash and equivalents, with restricted cash separate, and $22.374 million of cash used in operations during the first nine months. The comparable prior-year operating cash use was $23.468 million. Net loss for the nine months was $28.103 million, and accumulated deficit was approximately $303.1 million. Cash burn, accounting loss and accumulated deficit are different measures and should not be substituted for each other.
The cash position reflects financing as well as expenditure. In the first nine months, exercises of approximately 50.4 million warrants generated about $85.1 million. The filing reports no shares sold through the $150 million TD Cowen ATM to its filing date. The balance sheet therefore improved through an increase in the ownership denominator rather than through commercial product cash generation. The company recorded no licensing revenue during the nine-month period.
Management says cash and equivalents are sufficient for at least twelve months of current planned operations from issuance of the November financial statements. This is the company’s forward-looking funding assessment. It is not a promise that spending will stay flat or that financing cannot occur within that period. The same filing explains that development, regulatory and commercial preparations can require additional capital.
Merlintrader calculation: nine-month operating cash use of $22.374 million averages approximately $2.486 million per month. This is a retrospective average, with working-capital effects and development timing embedded in it. Extending that average mechanically across future years would assume unchanged programs, costs and commitments. After positive REGAL data, BLA preparation, manufacturing and further trials can change those assumptions. The company’s stated funding horizon is the appropriate attributed guidance.
Cash movements differ from accounting losses because financing, noncash items and working-capital changes affect the reconciliation. An earnings loss includes noncash items and timing effects, while a cash-flow statement records actual movement of funds. Equity-based compensation can add dilution even though it does not consume the same amount of cash in the period. These distinctions explain why a favorable headline cash balance should be read alongside shares, warrants and contractual obligations.
Merlintrader reading: the balance sheet creates room to execute, but the relevant next comparison is actual cash use against the development plan. A filing package, a clinical expansion and manufacturing readiness are separate uses of that room. The business has not become self-funding because a trial met its endpoint. A later financing should be assessed on the capital raised, ownership issued and purpose of funds, using its own dated disclosure.
September 30 financial statements and management liquidity discussion.
09 Debt, licensed rights and contingent obligations
SELLAS reports no financial debt in its September 30, 2026 balance sheet: total liabilities were $9.3 million, made up of accounts payable, accrued expenses and operating lease liabilities (Merlintrader reading of the Q3 filing). The most useful obligation analysis therefore extends beyond a headline debt number. The Q3 2026 filing describes operating liabilities, lease commitments and development-related licences. Milestone ceilings and royalties are conditional commitments, not all amounts currently due. Treating every possible future payment as present debt would overstate current obligations; ignoring them would understate the cost of eventual success.
The GenFleet agreement grants SLS009 rights outside mainland China, Hong Kong, Macau and Taiwan. The upfront and technology-transfer fee totaled $10 million and had been paid. Further development and regulatory milestones can reach $48 million across as many as three indications, with sales milestones of up to $92 million and tiered royalties. These amounts depend on the contractual triggers. They should be evaluated alongside the development program that would create the associated benefit and payment obligation.
GPS has a separate territorial arrangement with 3D Medicines for Greater China. At September 30, 2026 the Q3 filing reports $191.5 million of potential future development, regulatory and sales milestones, excluding royalties. The filing explicitly describes those milestones as variable and outside SELLAS’s control. They are not included here as cash available to fund the BLA or as a guaranteed future revenue stream.
The July arbitration dismissed SELLAS’s claims. The Q3 filing records approximately $0.7 million of the counterparty’s legal fees and $0.3 million of arbitration and administrative fees, paid during the third quarter, with the approximately $1 million charge included in general and administrative expenses. This is a completed historical cost. The ongoing licence economics should be read from the current contractual disclosures rather than inferred from the existence of the dispute.
Merlintrader reading: positive clinical data can increase the practical relevance of licensed rights, manufacturing commitments and eventual royalties. It does not convert milestone ceilings into revenue or make contractual costs disappear. A clear funding analysis separates cash currently held, liabilities currently recorded, future commitments and conditional payments. Any amendment to geographic rights or payment terms would need a new dated source before changing the model.
Q3 Form 10-Q: commitments, arbitration and licensing revenue.
10 SLS share dilution, warrants and the unused ATM
The Q3 filing reports 203,527,833 common shares outstanding at September 30, 2026 and 203,859,151 at November 11 on its cover. The later cover count is the current disclosed basic count for this analysis. Weighted-average shares used in earnings per share measure a period average and are not a substitute for either balance-date count. The difference matters when comparing cash per share, voting ownership or potential issuance.
At September 30, 8.122 million warrants remained outstanding. The disclosed groups were approximately 4.064 million October 2025 inducement warrants with a $2.00 exercise price and October 2030 expiry, 3.099 million March 2024 offering warrants at $1.41 with September 2029 expiry, and 0.959 million other warrants at a weighted $1.72 expiring between April 2027 and January 2029. These are contractual terms.
Subsequent to September 30, approximately 325,000 warrants were exercised at a weighted $1.41 for approximately $0.5 million, as disclosed in the November 12 filing. That event is separate from the quarter-end table. The same filing lists 2.651 million stock options and 3.310 million restricted stock units (RSUs), plus shares reserved for future incentive-plan and employee-purchase issuance. Outstanding awards, ungranted plan reserves and warrants are different categories; adding every authorization as if already issued would misstate the current share count.
The $150 million ATM is potential financing capacity, not cash already raised. SELLAS reported no sales under it through the filing date. Its eventual use could fund meaningful work while increasing the number of ownership claims. Actual dilution depends on the financing terms and issuance disclosed at the time.
Merlintrader reading: the first nine months’ warrant proceeds materially strengthened cash, while the share base also grew. The appropriate question after REGAL is whether additional capital supports development progress sufficient to justify the extra claims. Neither unused financing capacity nor remaining warrants establish that a sale will occur immediately. They do establish that basic shares alone do not describe all possible future issuance.
Q3 Form 10-Q: share count, warrant table and equity reserves.
11 Management, execution and governance after REGAL
SELLAS combines executive management with dedicated development, finance, regulatory, chemistry-manufacturing-and-controls (CMC), quality and legal functions. Following the positive REGAL topline of November 17, 2026, those functions must translate the clinical result into regulatory, manufacturing, financing and market-access decisions. The June 25, 2026 Form 8-K identifies the chief development and finance roles in the amended executive agreements. The positive trial still leaves material execution work before an approval or commercial launch.
On the constructive side, SELLAS completed REGAL enrollment, cleared the pre-specified interim analysis and every IDMC review so far, kept reporting the event count as the timeline moved, strengthened the balance sheet without using the ATM, presented SLS009 data at ASH, started first-line SLS009 enrollment, signed an agreement in January 2026 with IMPACT-AML, a European clinical network for acute myeloid leukemia, to run a study of about 40 patients testing SLS009 with azacitidine and venetoclax in newly diagnosed high-risk AML, and added pancreatic preclinical work (company release, January 14, 2026). On the skeptical side, it has a long history of financing needs and heavy dilution, it lost the 3D Medicines arbitration in July, and regulatory and operating outcomes remain uncertain. At the Annual Meeting on June 16, 2026, whose results SELLAS reported in a Form 8-K filed on June 18, stockholders approved 20 million additional shares under the 2026 Amended and Restated Equity Incentive Plan (named as in the Q3 Form 10-Q filed November 12, 2026), by about 42.9 million votes for to 27.3 million against; the September 30 filing reports approximately 18.957 million shares reserved for future incentive-plan issuance. About 15.9 million votes were cast against the advisory say-on-pay resolution. On June 16 the CEO also received a grant of 1,065,000 restricted stock units, vesting 25% on each December 1 starting in 2026; after it, his Form 4 shows 1,759,183 shares held directly. Executive agreements dated June 24 and disclosed in a Form 8-K filed on June 25 amended severance and change-of-control arrangements for the CEO, CFO and Chief Development Officer, a governance item that is not evidence of a transaction.
The June 25 executive-agreement filing identifies Angelos Stergiou as President and Chief Executive Officer, John Burns as Senior Vice President and Chief Financial Officer, and Dragan Cicic as Senior Vice President and Chief Development Officer. SEC executive agreements.
Merlintrader reading: the next execution test is turning a disclosed trial result into a complete data presentation, regulatory interaction and manufacturing preparation, while preserving financial flexibility. Change-of-control provisions are compensation arrangements; they do not prove that a transaction is being negotiated. Equity grants are compensation events, rather than evidence of an executive purchasing shares with personal funds.
Q3 governance and equity disclosures.
November 17 result and planned next steps.
June 18, 2026 Form 8-K: annual meeting votes · CEO Form 4: June 16, 2026 RSU award.
12 SLS institutional ownership, short interest and sentiment
State Street’s most recent disclosure is the Schedule 13G filed November 10, 2026, covering September 30. It reports 10,373,074 shares and 5.1% of the class, with shared voting power over 9,945,783 shares and shared dispositive power over 10,373,074. Filing date, ownership reference date and issuer share-count date are separate.
BlackRock’s October 27, 2026 Schedule 13G/A reports 15,872,685 shares and 7.9% as of September 30. The filing is a passive institutional disclosure under Rule 13d-1(b), rather than a claim to control the company. The percentage belongs to that filing’s stated reference date and denominator. Recalculating it using a later share count would create a different measure and should not be substituted for the filed percentage.
Vanguard Capital Management’s July 31, 2026 filing reports 9,666,278 securities, 5.19% as of June 30, and describes the holding in the form of warrants. That description must be preserved rather than silently recast as the same type of common-share holding as another institution’s report. Securities covered, voting power, dispositive power and beneficial-ownership calculations can differ. It is an older disclosed position, not a claim about a November transaction.
Nasdaq reports the following short positioning for the October 30, 2026 settlement: 57.13 million shares short and 6.70 days to cover. Settlement-based short interest is delayed data. Days to cover depends on the associated average-volume denominator and does not promise a squeeze or require all short positions to close in that many sessions. Short positions may include hedges, so their existence is not direct evidence that investors know the clinical outcome.
Merlintrader reading: passive ownership is evidence about the disclosed register, not proof of advance knowledge of REGAL or a merger. Retail discussions can identify questions worth checking, but message volume and conviction are not clinical evidence. Since November 17, the reported trial analysis is a more direct source for efficacy than any ownership narrative. A transaction claim still requires a definitive agreement or other attributable corporate disclosure.
State Street Schedule 13G, filed November 10, 2026.
BlackRock Schedule 13G/A, filed October 27, 2026.
13 Red flags and the Merlintrader assessment
Merlintrader reading, November 17, 2026. SELLAS now has a company-reported positive randomized overall-survival result for GPS, a separately developing CDK9 program and a stronger cash position than its earlier financing history might suggest. The analytical task is to follow the evidence from this point. The question of whether event 80 would occur was answered on October 28, 2026.
The first red flag is regulatory translation. A successful primary endpoint does not guarantee acceptance of the filing, an approval, a particular label or reimbursement. Detailed efficacy and safety, trial conduct, manufacturing and the proposed indication all matter. The company’s first-half 2027 BLA plan is meaningful guidance, with the uncertainty appropriate to a future submission.
The second is evidence quality beyond the headline. Median survival, hazard ratio, statistical significance, subgroup consistency and follow-up have different roles. The topline does not yet reproduce a complete clinical report. SLS009’s historical comparisons and small subgroups require particular care, and first-line outcomes cannot be assumed from a relapsed/refractory population. Pancreatic organoids remain laboratory work.
The third is financing and execution. Cash at September 30 is a dated resource; future operating plans can consume it at a different rate. The unused ATM, remaining warrants, options and RSUs make further issuance possible. Raising capital after favorable data could support the business, but it still changes the ownership denominator. Milestone ceilings under territorial licences should not be counted as assured cash.
The fourth is narrative risk. An institution’s filing, executive severance clause or manufacturing expenditure does not demonstrate a corporate transaction. The 3D Medicines arbitration cost and continuing licence terms require their own accounting. Neither a favorable topline nor a large retail following justifies replacing these distinctions with a single uncomplicated success story.
The Health Score below is 3.5 out of 5 after reassessment on November 17 following REGAL and the proposed public offering. Its five weighted pillars describe operational and financial robustness over twelve to eighteen months. It does not measure clinical approval probability, expected security returns or an appropriate personal investment. The score can remain constrained by dilution and execution risk even when a major clinical milestone improves.
The evidence that would strengthen this reading is concrete: a complete REGAL presentation consistent with the topline, a clearly documented FDA path, a prepared filing, useful SLS009 results and disciplined use of capital. Contrary evidence would require changing the analysis. These are conditional assessments intended to make the company understandable, without a recommendation to transact in its securities.
Merlintrader Health Score · $SLS
3.5out of 5
Reassessed November 17, 2026 after REGAL topline and the proposed public offering. Balance sheet 4.0, Catalyst 4.0, Liquidity 3.0 and Execution 4.0; Dilution 2.0 because a specific proposed primary offering adds issuance risk beyond unused capacity. Merlintrader calculation: 4.0×30% + 4.0×30% + 2.0×20% + 3.0×10% + 4.0×10% = 3.50, displayed as 3.5/5. The offering is not treated as completed or as cash received. This measures financial and operational robustness over twelve to eighteen months, not an investment recommendation. Company offering announcement, November 17, 2026.
Red flags
- REGAL’s positive result is a topline: the FDA may not agree with the company’s analyses or filing strategy, and the full data and secondary endpoints are not yet public.
- First-line SLS009 had enrolled 40 of 80 patients at the November 12 update; the topline sample size is unspecified.
- Pancreatic-cancer findings remain preclinical.
- Cash is a September 30 figure; spending and the share count can change after the filing dates.
- Warrants, equity awards and the ATM create further dilution capacity.
- High short positioning can intensify volatility in either direction.
- The proposed November 17 public offering adds a separate dilution and financing-execution risk; no pricing or completion was announced in the proposed-offering release.
SLS Stock FAQ: SELLAS Life Sciences Questions Answered
What did SELLAS report from the REGAL trial?
On November 17, 2026, SELLAS announced that the Phase 3 REGAL trial met its overall-survival primary endpoint. Median overall survival was 24.0 months with GPS versus 14.7 months with best available treatment, a 41% reduction in the risk of death (hazard ratio 0.59, two-sided p=0.035), among 126 randomized patients. The company plans to meet the FDA and to submit a BLA in the first half of 2027; detailed results are to be presented at an upcoming medical conference. Details. Form 8-K.
Are SELLAS’s GPS and SLS009 FDA approved?
As of November 17, 2026, SELLAS’s GPS and SLS009 remain investigational cancer therapies without FDA approval. GPS met the primary endpoint of the Phase 3 REGAL trial, and SELLAS plans to meet the FDA and to submit a BLA in the first half of 2027; SLS009, also called tambiciclib, is a selective CDK9 inhibitor in clinical development. Details.
How much cash does SELLAS have, and how long will it last?
SELLAS held $134.7 million in cash and equivalents at September 30, 2026; management says this funds planned operations for at least twelve months from the November financial statements. Nine-month operating cash use was $22.374 million. These historical figures differ from the current cash balance and future spending. Details.
Is SLS stock at risk of dilution?
Yes: SELLAS reported 8.12 million outstanding warrants at September 30, 2026 and an unused $150 million ATM through the November 12 filing date; the share count reached 203,859,151 at November 11. Equity awards and reserved plan shares add potential issuance. Future warrant exercises or ATM sales can increase the share count. Details. On November 17 SELLAS separately commenced a proposed $150 million public offering, plus an intended $22.5 million option; the announcement did not fix pricing or completion. Company offering announcement, November 17, 2026.
When does SELLAS report earnings?
SELLAS reported third-quarter 2026 results on November 12, 2026, for the quarter ended September 30; as of that date it had not announced its next earnings date. The SLS009 readout window and the GPS regulatory steps are separate from an earnings schedule. Details.
What does SELLAS Life Sciences do?
SELLAS Life Sciences develops cancer treatments, including the WT1-targeting immunotherapeutic galinpepimut-S and the selective CDK9 inhibitor SLS009. Its lead clinical programs focus on acute myeloid leukemia, with GPS evaluated as maintenance treatment after a second complete remission. Details.
Did SELLAS’s REGAL 80th event mean GPS succeeded?
No: the October 28, 2026 announcement confirmed the prespecified trigger for REGAL’s final survival analysis, rather than an efficacy result. The result came on November 17, 2026, when SELLAS reported that REGAL met its overall-survival primary endpoint (hazard ratio 0.59, two-sided p=0.035). Details.
When will SELLAS report first-line SLS009 trial results?
SELLAS guides first-line AML Phase 2 SLS009 topline to Q4 2026, without an exact date, and reiterated that timing on November 4 and November 12. Enrollment was 28 of 80 patients at August 10 and 40 of 80 at the November 12 update. The broader trial record’s estimated December 30, 2026 primary completion is separate from that topline window. Details (August 11 release). Details (November 12 release). Trial record.
Primary sources
- Company offering announcement, November 17, 2026
- SELLAS positive pivotal Phase 3 REGAL topline results, November 17, 2026 (company release, Exhibit 99.1 to Form 8-K)
- SELLAS Form 8-K, November 17, 2026 (REGAL topline)
- SELLAS third-quarter 2026 results and corporate update, November 12, 2026 (REGAL topline expected in November)
- SELLAS Q3 2026 Form 10-Q, filed November 12
- SELLAS SLS009 Phase 2 data at ASH 2026, November 4, 2026 (company release, full wire text)
- SELLAS REGAL announcement, October 28, 2026
- SELLAS Q2 2026 Form 10-Q, filed August 11
- SELLAS second-quarter results, August 11, 2026
- BlackRock Schedule 13G/A, filed October 27, 2026
- SLS009 pancreatic-cancer data, September 25, 2026
- SLS009 conference abstracts, September 2, 2026
- 3D Medicines interim-results filing, August 31, 2026
- REGAL, NCT04229979
- SLS009, NCT04588922
- Nasdaq short-interest report
- SLS009 ASH 2025 Phase 2 data
- State Street Schedule 13G, filed November 10, 2026 (September 30 ownership)
- SELLAS executive-agreement filing, June 25, 2026
Disclaimer. This content is published by Merlintrader for educational and informational purposes only. It is independent journalism and research. It does not constitute investment advice, an investment recommendation, an offer or a solicitation to buy or sell any security, and it is not a research report within the meaning of applicable United States securities regulation. Nothing here should be read as a recommendation to buy, sell or hold $SLS or any other security.
Figures are taken from public filings with the U.S. Securities and Exchange Commission, company press releases and market-data providers, and are stated with their reference dates. Data can change without notice, and figures published before a results release become outdated the moment that release is issued. Merlintrader makes no representation that the information is complete or current at the time of reading. Readers should verify every figure against the primary source before acting on it.
Biotechnology and healthcare companies carry binary risk. Clinical trials fail, regulatory decisions go against the applicant, approval does not guarantee commercial uptake, and development-stage companies frequently raise equity at whatever price the market will bear. A single readout can change the value of the business overnight in either direction, and companies at this stage can lose all of their value. Every reader is responsible for their own decisions and should consult a licensed financial adviser where appropriate.
Merlintrader may hold positions in securities mentioned. Some links on this page are affiliate or referral links, including those to Finviz and Stocktwits, which may generate a commission at no cost to the reader. Full legal information is available on the disclaimer and terms of use and privacy pages.



